Stay updated on Alpha Study: Afatinib & Pembrolizumab in HNSCC Clinical Trial
Sign up to get notified when there's something new on the Alpha Study: Afatinib & Pembrolizumab in HNSCC Clinical Trial page.

Latest updates to the Alpha Study: Afatinib & Pembrolizumab in HNSCC Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1%
- Check23 days agoNo Change Detected
- Check31 days agoChange DetectedThe web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference2%
- Check38 days agoChange DetectedThe website has been updated from version 2.14.1 to 2.14.2.SummaryDifference0.1%
- Check52 days agoChange DetectedDifference0.1%
- Check59 days agoChange DetectedThe website has updated the 'type of intervention' feature from version v2.13.3 to v2.14.0, indicating a significant change in its functionality.SummaryDifference0.3%
- Check88 days agoChange DetectedThe website has been updated from version 2.13.2 to 2.13.3.SummaryDifference0.1%
Stay in the know with updates to Alpha Study: Afatinib & Pembrolizumab in HNSCC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Alpha Study: Afatinib & Pembrolizumab in HNSCC Clinical Trial page.